MACROGENICS INC 8-K

What Happened
MacroGenics, Inc. announced the closing of the previously disclosed sale of certain assets and liabilities related to its GMP manufacturing and CDMO operations to Bora Pharmaceuticals Co., Ltd. and Bora Biologics USA, LLC. The Asset Purchase Agreement dated May 11, 2026 closed effective June 30, 2026, and the purchaser paid $122.5 million at closing (before transaction fees/expenses and subject to customary post‑closing adjustments). The sale covers the manufacturing facility in Rockville, MD and related warehouse operations in Frederick, MD; research and related assets were excluded from the transaction.

Key Details

• Buyer: Bora Pharmaceuticals Co., Ltd. and Bora Biologics USA, LLC.
• Purchase price: $122.5 million at closing, before fees and subject to post‑closing adjustments.
• Effective date: June 30, 2026; Purchase Agreement dated May 11, 2026.
• Corporate disclosures: press release dated July 2, 2026 (Exhibit 99.1) and unaudited pro forma consolidated financials reflecting the disposition (Exhibit 99.2).

Why It Matters
This is a material divestiture: MacroGenics has transferred its CDMO/GMP manufacturing operations and the related revenue/cost streams to the purchaser, which will affect the company’s future operating profile and reported results. The $122.5M proceeds (net of fees and any adjustments) will affect MacroGenics’ liquidity and balance sheet; investors should review the furnished unaudited pro forma financial statements to understand the immediate financial impact and any changes to revenue sources going forward.